Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 705 - 712 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC3897 | 6,2',4'-Trimethoxyflavone |
|
Aryl hydrocarbon receptor antagonist (EC<sub>50</sub> = 0.9 <span class='symbol'>μ</span>M). Exhibits no short term agonist activity and no species or promoter dependence.
|
|
| BCC3898 | MeBIO |
|
Control analog of 6-bromoindirubin-3'-oxime (BIO). Displays minimal activity against CDK1/Cyclin B, GSK-3 <span class='symbol'>α</span>/<span class='symbol'>β</span>, and CDK5/p25 (IC<sub>50</sub> values are 92.0, 44-100 and >100 <span class='symbol'>μ</span>M respectively). Aryl hydrocarbon receptor (AhR) agonist; causes redistribution of AhR to the nucleus.
|
|
| BCC3899 | L-Kynurenine |
|
Tryptophan catabolite; endogenous activator of the aryl hydrocarbon receptor (AhR). Immunosuppressant; suppresses allogeneic T cell proliferation.
|
|
| BCC3900 | DiMNF |
|
Selective aryl hydrocarbon receptor (AHR) modulator (SAhRM). Suppresses expression of CD55 and CD46 induced by IL-1<span class='symbol'>β</span> in an inflammatory tumor cell microenvironment; exhibits no effect on basal CD55 or CD46 expression.
|
|
| BCC3901 | Phortress |
|
Prodrug of the antitumor agent 5F 203, which acts via binding to aryl hydrocarbon receptors. Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells.
|
|
| BCC3902 | ITE |
|
Endogenous aryl hydrocarbon receptor (AhR) agonist (Ki = 3 nM). Decreases Oct4 levels in U87 glioblastoma cells. Induces stem-like cancer cell differentiation in U87 tumor spheres and inhibits ovarian cancer cell proliferation in vitro. Suppresses tumor growth in U87 and OVCAR-3 cell xenografts in mice. Also inhibits TGF-β-induced human myofibroblast differentiation.
|
|
| BCC3911 | CGK733 |
|
Originally defined as a selective inhibitor of ATR and ATM kinases. Induces cell death in prematurely senescent breast cancer cells. Decreases p21CIP1 levels in premature senescent MCF-7 and HCT-116 cells; also exhibits antiproliferative activity in a range of cancer cell lines. Blocks camptothecin-induced p53 phosphorylation and protects cells from camptothecin-induced apoptosis.
|
|
| BCC3914 | Bafilomycin A1 |
|
Highly potent, selective inhibitor of vacuolar H<sup>+</sup>-ATPases (IC<sub>50</sub> = 0.6 - 1.5 nM in bovine chromaffin granules). Selective for v-ATPase over other ATP hydrolyzing enzymes such as F-ATPases and the H<sup>+</sup>/K<sup>+</sup>-ATPase (P-ATPase). Thought to inhibit autophagy either by blocking autophagosome-lysosome fusion (in H4IIE cells), or by blocking lysosomal degradation.
|
|